Modulating Inflammation in Neuro-Trauma
NCT: NCT07510074 · NOT_YET_RECRUITING
Brief Summary
MINT is a single-site, prospective, randomized, double-blind, sham-controlled pilot trial evaluating the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with moderate to severe traumatic brain injury (GCS 3-12). Participants will be randomized to receive either active taVNS or sham stimulation using the same device. The primary objective is to assess the safety and feasibility of taVNS implementation in the acute TBI setting. Secondary objectives include exploratory measurement of serum inflammatory and neuronal injury biomarkers and assessment of functional outcome using the Extended Glasgow Outcome Scale at hospital discharge.
Frequently Asked Questions
What is Modulating Inflammation in Neuro-Trauma?
Modulating Inflammation in Neuro-Trauma is a clinical trial registered under NCT07510074. Current status: NOT_YET_RECRUITING.
What is the status of NCT07510074?
The current status of NCT07510074 (Modulating Inflammation in Neuro-Trauma) is: NOT_YET_RECRUITING.
When did Modulating Inflammation in Neuro-Trauma start?
Modulating Inflammation in Neuro-Trauma started on 2026-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.